U.S. life sciences firm Illumina will have to divest biotechnology company Grail after an EU veto of the $7.1 billion acquisition over concerns it would hurt competition and stifle innovation.
https://www.pharmalive.com/wp-content/uploads/2022/09/ReutersIllumina9-6-2022.jpg8001200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-09-06 08:38:212022-09-06 09:32:44Illumina will have to divest Grail after EU blocks takeover
